Sentences with phrase «sofosbuvir in»
Another paper in the same edition of the NEJM reports two additional studies of sofosbuvir - containing therapy, one evaluating a 12 week regimen of peginterferon, ribavirin and sofosbuvir in patients with genotypes 1, 4, 5 and 6 who have never been treated before; the other reporting results of a trial comparing 24 weeks of peginterferon and ribavin with 12 weeks of sofosbuvir and ribavirin in treatment naïve patients with genotypes 2 and 3.
https://www.sciencedaily.com/ Not exact matches
Gilead Sciences» first offering, Sovaldi (sofosbuvir), was approved in the U.S. in December.
It has confirmed that 24 weeks is the optimal duration for a sofosbuvir and ribavirin combination in GT - 3 patients, whilst also finding that sofosbuvir and ribavirin with peginterferon for 12 weeks resulted in the highest SVR12 rates observed to date in a Phase 3 study,» said Professor Tom Hemming Karlsen, Scientific Committee Member, European Association for the Study of the Liver (EASL).
Results presented today at The International Liver Congress ™ 2015 demonstrate that hepatitis C (HCV)- infected genotype - 3 (GT - 3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
«Sofosbuvir and peginterferon / ribavirin demonstrates virologic response rates in G3 hep C patients.»
Sofosbuvir, made by Gilead Sciences in Foster City, California, debuted last December at $ 1,000 a pill — $ 84,000 for a 12 - week course.
In March, Gilead announced a deal with Egypt to provide sofosbuvir at $ 900 for a 12 - week course.
Meanwhile, the Initiative for Medicines, Access & Knowledge, a non-profit group in New York, has filed a lawsuit with India's patent office seeking to prevent Gilead from receiving a patent for sofosbuvir.
«In distinct contrast to the situation in the U.S., Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended two highly effective sofosbuvir - based regimens for Pharmaceutical Benefits Scheme (PBS) listing, without drug use or disease stage - related restrictions,» said co-author and professor Greg Dore of the Kirby InstitutIn distinct contrast to the situation in the U.S., Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended two highly effective sofosbuvir - based regimens for Pharmaceutical Benefits Scheme (PBS) listing, without drug use or disease stage - related restrictions,» said co-author and professor Greg Dore of the Kirby Institutin the U.S., Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended two highly effective sofosbuvir - based regimens for Pharmaceutical Benefits Scheme (PBS) listing, without drug use or disease stage - related restrictions,» said co-author and professor Greg Dore of the Kirby Institute.
«We are achieving the same or higher cure rates in many patients with sofosbuvir, compared to interferon, and we are doing it in half the time with a drug that has a remarkable safety profile.»
In September 2017, the government of Malaysia issued a «government - use» license on sofosbuvir patents to allow 400,000 people living with hepatitis C in Malaysia to access generic HCV regimens in public hospitalIn September 2017, the government of Malaysia issued a «government - use» license on sofosbuvir patents to allow 400,000 people living with hepatitis C in Malaysia to access generic HCV regimens in public hospitalin Malaysia to access generic HCV regimens in public hospitalin public hospitals.
Study results show the response rate for all treated patients with sofosbuvir was 78 percent compared to 0 percent in participants treated with placebo agents.
In our analysis, we found that most states with known sofosbuvir Medicaid reimbursement requirements impose undue restrictions on eligible recipients.»
«Ledipasvir plus sofosbuvir: Hint of added benefit in further patient group.»
«The cohort study has found that the sofosbuvir / daclatasvir combination is associated with a high rate of SVR4 in difficult - to - treat patients infected by genotype - 1 hepatitis C.
A study presented today that evaluated an investigational dosage of once - daily ledipasvir 45 mg / sofosbuvir 200 mg (LDV / SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99 % of children (n = 89/90) had undetectable levels of HCV - RNA 12 weeks after treatment.
In a more advanced trial, 12 weeks of sofosbuvir plus ribavirin yielded the same results as 24 weeks of interferon plus ribavirin: 67 percent of patients had no evidence of the virus in their blood (although side effects such as fever and depression were fewer among patients who did not receive interferonIn a more advanced trial, 12 weeks of sofosbuvir plus ribavirin yielded the same results as 24 weeks of interferon plus ribavirin: 67 percent of patients had no evidence of the virus in their blood (although side effects such as fever and depression were fewer among patients who did not receive interferonin their blood (although side effects such as fever and depression were fewer among patients who did not receive interferon).
In Egypt, which has the world's highest rate of hepatitis C, sofosbuvir costs $ 300 for a 28 - day supply.
For this study, the team will test Sofosbuvir, a new drug, and Ribavirin, which is used in the treatment with interferon.
For example, sofosbuvir's manufacturer, Gilead Sciences Inc. of Foster City, California, sells the drug to Egypt at a discount and allows generic manufacturers in India to produce and sell in 91 poorer countries.
In subsequent tests using an immunodeficient mouse model infected by Zika, intravenous injections of sofosbuvir significantly reduced viral loads in blood serum compared to a placebo grouIn subsequent tests using an immunodeficient mouse model infected by Zika, intravenous injections of sofosbuvir significantly reduced viral loads in blood serum compared to a placebo grouin blood serum compared to a placebo group.
In tests using human neural progenitor cells (NPCs)-- self - renewing, multipotent cells that generate neurons and other brain cell types — the scientists found that exposure to sofosbuvir not only rescued dying NPCs infected with the Zika virus, but restored gene expression linked to their antiviral response.
Moreover, fetuses of Zika - infected pregnant mice did not show detectable Zika virus amplification in the sofosbuvir - treated group.
The higher cure rate and lessened side - effects of treating patients with an all - oral combination of ledipasvir and sofosbuvir (LDV / SOF) results in greatly reduced absenteeism and improved workplace productivity that can translate into enormous benefit, according to the new economic model used by researchers at Inova Fairfax Medical Campus, VA..
Sofia will receive the 2016 Lasker - DeBakey Award on Sept. 23 along with Charles Rice, Ph.D., of Rockefeller University and Ralf Bartenschlager, Ph.D., of Heidelberg University, who were recognized for their work in developing systems essential to hepatitis C research, which Sofia used in developing the drug, sofosbuvir.
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options; David R. Nelson, MD, University of Florida.
The ledipasvir / sofosbuvir combination, Harvoni ®, is now FDA - approved for numerous types of HCV infection, including the most common form in the US and Europe.
Examples of DAAs, which come in pill form, are Olysio (simeprevir); Sovaldi (sofosbuvir), which is used in combination with Olysio; Daklinza (daclatasvir); and Harvoni (a combination of ledipasvir and sofosbuvir).